Dean J. Mitchell - 15 Jun 2022 Form 4 Insider Report for ImmunoGen, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 15 Jun 2022
Net transaction value: +$148,280
SEC form: 4
Accepted by SEC: 17 Jun 2022, 16:19:27 UTC
Prior SEC filing: 15 Jun 2022
Next SEC filing: 05 Jul 2022
Source filing: View source filing
Reporting owner signature: /s/ Renee Lentini, Attorney-in-Fact

Key filing fact

Dean J. Mitchell filed Form 4 for ImmunoGen, Inc. on 17 Jun 2022.

Key facts

This page summarizes Dean J. Mitchell's Form 4 filing for ImmunoGen, Inc..
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 17 Jun 2022, 16:19.

Change

Previous filing in this sequence was filed on 15 Jun 2022.
Current net transaction value: +$148,280.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMGN transaction Derivative

Deferred Share Unit

Award

Transaction value: $0
Shares: +15,000
Change %: +13%
Price: $0.000000
Shares after: 133,172
Date: 15 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $0.000000
Footnotes: F1, F2, F3

IMGN transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $148,280
Shares: +44,000
Change %
Price: $3.37^*
Shares after: 44,000
Date: 15 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 44,000
Exercise price: $3.37
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.

Footnote F2

The deferred share units vest ratably over a one-year period in quarterly increments beginning on 9/1/22, contingent upon the individual remaining a director as of each vesting date.

Footnote F3

The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.

Footnote F4

Exercisable as to 11,000 shares on each of 9/1/22, 12/1/22, 3/1/23, and 6/1/23, contingent upon the individual remaining a director as of each vesting date.